

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED  
Representative: Joji Nakayama, President and CEO  
(Code no.: 4568, First Section of Tokyo and Osaka Stock Exchanges)  
Please address inquiries to Noriaki Ishida, Corporate Officer,  
Vice President, Corporate Communications Department  
Telephone: +81-3-6225-1126  
<http://www.daiichisankyo.com>

**Daiichi Sankyo's Japan Research Foundation for Clinical Pharmacology Awards Its  
6th Annual Clinical Pharmacology Research Award**

**Tokyo, Japan (June 25, 2013)** – Daiichi Sankyo Company, Limited today announced that its affiliate, the Japan Research Foundation for Clinical Pharmacology\* (headquarters, Tokyo; Director General, Kiyoshi Morita), has awarded its 6th “Japan Research Foundation for Clinical Pharmacology Research Award” to five young researchers.

Award recipients are selected from research papers submitted from projects funded with subsidies from the foundation. Innovative research projects with expectations for future development are eligible for the award.

The Foundation hopes that this award will motivate young clinical pharmacology researchers who are involved in the establishment of appropriate drug treatments and encourage future research results. The awards ceremony and presentation of research themes will be held on November 5, 2013.

\*The mission of the Foundation is to promote clinical pharmacology and foster the development of clinical pharmacologists. The Foundation was established in 1975 and has worked on a variety of projects relating to clinical pharmacology, including promotion of research, overseas studies for Japanese researchers, and international collaborations in Asia.

# Recipients of the 6th Japan Research Foundation for Clinical Pharmacology Research Award

Recipient	Organization	Research theme
Yuji Ishii	Laboratory of Molecular Life Sciences Graduate School of Pharmaceutical Sciences Kyushu University	Novel mechanism of inter-individual difference in drug responses: modulation of cytochrome P450 3A4 function by UDP-glucuronosyltransferases
Mitsushige Sugimoto	Division of Gastroenterology First Department of Medicine Hamamatsu University School of Medicine	Effectiveness of personalized eradication treatment for patients infected with <i>Helicobacter pylori</i>
Masayoshi Souri	Department of Molecular Patho-Biochemistry and Patho- Biology, Yamagata University School of Medicine	Change in the plasma levels of protein Z system, a novel anti-activated factor X system
Hiroshi Furukawa	Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization	Genetic association study on drug-induced interstitial lung diseases in rheumatoid arthritis patients
Hiroyuki Mizuguchi	Department of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University	Development of mature hepatocytes derived from human ES/iPS cells and prediction of drug-induced liver toxicities